Transaction details
Todd Alfred Carter, Chief Scientific Officer of Voyager Therapeutics (NASDAQ: VYGR), sold 4,174 shares of the company's common stock on February 24, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The sale produced total proceeds of $15,694 based on a weighted average price of $3.76 per share. Reported trade prices ranged between $3.61 and $3.86.
Context and ownership
Following this disposition, Carter holds 145,718 shares directly in Voyager Therapeutics. The filing states the sale was conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units. The trades were carried out under a pre-arranged automatic sale instruction that Carter adopted on May 12, 2025, and the filing notes that the transactions were not discretionary.
Market reaction and valuation signals
Since the February 24 transaction, Voyager Therapeutics shares have appreciated and are currently trading at $4.19, representing a 19.59% gain over the prior week. InvestingPro analysis included in the filing indicates a Fair Value estimate of $4.55, suggesting the stock is trading below that calculated level. The company receives a "FAIR" financial health rating in that analysis, and one highlighted balance sheet item is that Voyager holds more cash than debt. The InvestingPro note also references that this assessment is among 11 ProTips available to subscribers.
What the filing says about intent
The Form 4 specifies that the sale was executed to meet tax withholding liabilities connected to RSU vesting and that the transactions were performed under a previously established automatic instruction. As such, the filing characterizes the sales as non-discretionary and tied to plan mechanics rather than an independent, ad hoc decision by the officer.
Analysis limitations
The information available in the filing documents the mechanics, timing, and stated purpose of the sale, and it includes the subsequent market price and a third-party valuation snapshot. The filing does not provide additional commentary or forward-looking statements from the officer or the company.